On May 2, 2023 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, reported it will announce financial results for the first quarter 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets (Press release, Aclaris Therapeutics, MAY 2, 2023, View Source [SID1234630822]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will conduct a conference call at 8:00 AM ET on the same day to discuss Aclaris’ financial results and to provide a corporate update, including a summary of final results from the Phase 2a trial of zunsemetinib (ATI-450) in subjects with moderate to severe hidradenitis suppurativa. The conference call will be webcast live over the internet and can be accessed by logging into the "Investors" page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. The webcast will be archived for at least 30 days on the Aclaris website.